Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jiayao Ni
Institutions:
Nanjing University of Chinese Medicine,
Nanjing Drum Tower Hospital,
Nanjing University
Observed institutions:
Nanjing University of Chinese Medicine,
Nanjing Drum Tower Hospital,
Jiangsu Province Hospital,
Nanjing University
ORCID:
0009-0004-4845-3006
Observed ORCID:
0009-0004-4845-3006
OpenAlex ID:
A5104329588
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial
2024
·
Huizi Sha
, Fan Tong
, et al.
·
Signal Transduction and Targeted Therapy
·
42
Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
2024
·
Qin Wang
, Fan Tong
, et al.
·
Cancer Immunology Immunotherapy
·
12
Making “cold” tumors “hot”- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report
2023
·
Fan Tong
, Yi Sun
, et al.
·
Frontiers in Immunology
·
9
PDF
Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET/CT, DNA mutation, and CA199
2025
·
Liang Qi
, Xiang Li
, et al.
·
Cancer Cell International
·
6
PDF
Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer
2026
·
Jingjing Chen
, Lu Zou
, et al.
·
Frontiers in Oncology
·
5
PDF
Personalized ctDNA monitoring to assess the recurrence of early stage pancreatic cancer after surgery.
2025
·
Juan Du
, Lu Zou
, et al.
·
Journal of Clinical Oncology
·
3
Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2025
·
Jiayao Ni
, Yi Sun
, et al.
·
Clinical Cancer Research
·
2
PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with potentially resectable pancreatic cancer: A single-arm phase 2 study.
2024
·
Juan Du
, Jiayao Ni
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Data from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Table S4 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Table S2 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Table S3 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Table S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Figure S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Information1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Supplementary Figure S2 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026
·
Jiayao Ni
, Yi Sun
, et al.
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.
2024
·
Juan Du
, Fan Tong
, et al.
·
Journal of Clinical Oncology
Brg1 regulates fibroblast-myofibroblast transition to promote renal fibrosis
2023
·
Xiaoyan Wu
, Yajun Luo
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Show more works
View as search
Works count:
18
Citation count:
80
H-index:
5
I10-index:
2
Year
Topic
Type